Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT04185883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04185883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 17, 2019
Completion date
December 5, 2027
Enrollment
610 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, kirsten rat sarcoma (kras) pg12c mutation